immatics appoints Dr Rainer Kramer as its new chief business officer
pharmafile | April 12, 2012 | Appointment | Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing |
immatics biotechnologies, a biopharma company developing therapeutic cancer vaccines, has appointment Dr Rainer Kramer as its new chief business officer.
In this newly created role, Dr Kramer will lead immatics’ Business Development Unit in order to create optimal value from the company’s pipeline of therapeutic cancer vaccines.
He has many years of business development experience within the pharma industry and joins the firm from Signature Diagnostics, an oncology diagnostics company where he was CBO.
Before that, he was VP of business development at Jerini, where he was responsible for all licensing, partnering, and alliance management activities, and played a key role in the sale of the company to Shire in 2008.
Before joining Jerini, he held various business development and research positions at MorphoSys, Martinsried, and Amgen.
Dr Kramer holds a Diploma in Molecular Biology from the University of Regensburg and a PhD from the Max-Planck-Institute for Neurobiology.






